Earnings ·
First Tracks Biotherapeutics reported financial results for the three and six months ended June 30, 2026
TRAXVFirst Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics reported financial results for the three and six months ended June 30, 2026. The company held $168.0 million in cash, cash equivalents, and investments as of June 30, 2026. Research and development expenses were $25.6 million for the quarter and $59.6 million for the six-month period, while general and administrative expenses rose to $9.3 million and $28.1 million respectively due to separation-related legal costs. The net loss was $33.4 million ($0.95 per share) for the quarter and $83.9 million ($2.40 per share) for the six-month period. Clinically, the U.S. FDA granted Fast Track designation for ANB033 in celiac disease, Cohort 1 enrollment is complete with top-line data expected in Q4 2026, and Cohort 2 data is anticipated in Q1 2027. The company maintains a cash runway into Q2 2028. First Tracks Biotherapeutics operates as a clinical-stage biotechnology company developing antibody therapeutics for autoimmune and inflammatory diseases.